AI
PACB icon

Atria Investments’s Pacific Biosciences PACB Stock Holding History

Atria Investments’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,496
Closed -$51.4K – 2125
2025
Q4 		$51.4K Buy
27,496
+5,735
+26% +$11K ﹤0.01% 2015
2025
Q3 		$27.9K Sell
21,761
-410
-2% -$555 ﹤0.01% 2002
2025
Q2 		$27.5K Sell
22,171
-157
-0.7% -$181 ﹤0.01% 1981
2025
Q1 		$26.3K Sell
22,328
-3,926
-15% -$6.02K ﹤0.01% 1889
2024
Q4 		$48K Buy
26,254
+4,286
+20% +$8.37K ﹤0.01% 1842
2024
Q3 		$37.3K Buy
21,968
+10,138
+86% +$16.7K ﹤0.01% 1892
2024
Q2 		$16.2K Buy
+11,830
New +$23.9K ﹤0.01% 1904

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Atria Investments's PACB Position: Q1 2026 in Review

Atria Investments sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 27,496 shares — an estimated $51.4K sold.

Atria Investments first reported a position in PACB in Q2 2024 and held it in 7 quarters. The position peaked at $51.4K in Q4 2025. 231 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Atria Investments reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
  • Atria Investments sold 27,496 Pacific Biosciences shares in Q1 2026, an estimated $51.4K.
  • Atria Investments first reported a position in Pacific Biosciences in Q2 2024 and held it in 7 quarters.
  • Atria Investments's Pacific Biosciences position peaked at $51.4K in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.